Tivic

Executive Summary

Tivic is a late-stage immunotherapeutics company focused on harnessing the innate immune system to prevent cell death in bone marrow and epithelial tissues. Its lead asset, Entolimod™, is a TLR5 agonist in development for Acute Radiation Syndrome (ARS) under the FDA's Animal Rule, which allows approval based on animal efficacy data when human trials are not feasible. The company is based in San Francisco and was founded in 2016. Tivic's platform has potential extensions into oncology and age-related conditions, offering a pipeline beyond ARS. With a targeted mechanism and regulatory pathway aligned with national security interests, Tivic represents a compelling opportunity in biodefense and radiation countermeasures.

Upcoming Catalysts (preview)

• Q3 2026FDA filing or pre-NDA meeting for Entolimod in ARS60% success
• Q4 2026Publication of pivotal animal study results70% success
• Q3 2026Strategic partnership or government contract for Entolimod50% success